Qing Zhou

Yi-long Wu, Jin-Ji Yang, S. Chuai, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non-Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705).

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2022, Clinical lung cancer.

Genotyping of cerebrospinal fluid associated with osimertinib response and resistance for leptomeningeal metastases in EGFR-mutated non-small cell lung cancer.

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel.

Ying Cheng, Yi-long Wu, B. Han, 2018, Translational lung cancer research.

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

Jin-Ji Yang, K. Yin, Chongrui Xu, 2022, BMC Medicine.

Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD‐L1‐positive locally advanced or metastatic non–small‐cell lung cancer: KEYNOTE‐042 China Study

T. Mok, Yi-long Wu, Li Zhang, 2020, International journal of cancer.

An Autologous Therapeutic Dendritic Cell Vaccine Transfected with Total Lung Carcinoma RNA Stimulates Cytotoxic T Lymphocyte Responses Against Non-Small Cell Lung Cancer

Yi-long Wu, Chongrui Xu, S. An, 2009, Immunological investigations.

Benign disease prone to be misdiagnosed as malignant pulmonary nodules: Minute meningothelioid nodules

Xing Gao, Li-xu Yan, Si-yun Wang, 2019, Thoracic cancer.

CTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC

Y. Shu, Y. Wu, N. Yang, 2019, Annals of Oncology.

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.

Ying Cheng, Yi-long Wu, Zhidong Liu, 2018, The Lancet. Oncology.

Poor prognosis of intra‐tumoural TRBV6‐6 variants in EGFR‐mutant NSCLC: Results from the ADJUVANT‐CTONG1104 trial

Yangqiu Li, Xue-Ning Yang, W. Zhong, 2022, Clinical and translational medicine.

[Chinese Expert Consensus on Management of Special Adverse Effects  Associated with Lorlatinib].

Z. Hong, Yong Li, Zhe Liu, 2022, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Lorlatinib for Previously Treated ALK -Positive Advanced NSCLC: Primary Ef ﬁ cacy and Safety From a Phase 2 Study in People ’ s Republic of China

C. Bai, He-long Zhang, Jian-hua Chang, 2022 .

Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2021, European journal of cancer.

Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis.

T. Mok, Yi-long Wu, K. Nakagawa, 2019, Future oncology.

Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.

Yi-long Wu, Jian-hua Chang, Dong Wang, 2022, The Lancet. Oncology.

Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients

Yi-long Wu, Jin-Ji Yang, Y. Shao, 2020, Biomarker Research.

晚期非小细胞肺癌免疫治疗的一线联合治疗

Qing Zhou, Xiaoxiao Peng, Xiao-xiao Peng, 2018, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2020, Journal of thoracic disease.

Identification of TCR rearrangements specific for genetic alterations in EGFR-mutated non-small cell lung cancer: results from the ADJUVANT-CTONG1104 trial

Yangqiu Li, Xue-Ning Yang, W. Zhong, 2022, Cancer Immunology, Immunotherapy.

Bone metastasis unique plasma exosomal microRNA signature in non-small cell lung cancer

Xue Wu, Y. Shao, Xuchao Zhang, 2019, Journal of Clinical Oncology.

Distribution and prognosis of uncommon metastases from non-small cell lung cancer

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2016, BMC Cancer.

Treatment Pattern and Overall Survival of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Multicentric Real-World Study in China (CTONG1506)

Yi-long Wu, P. Yu, D. Zhong, 2020 .

A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2019, Lung cancer.

Predictive value of TCR Vβ-Jβ profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trial

Yangqiu Li, Yi-long Wu, Xue-Ning Yang, 2022, JCI insight.

PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma

Yu Chen, Ji Chen, Jin-Ji Yang, 2022, Frontiers in Immunology.

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Jianying Zhou, Erdem Goker, Jun Zhao, 2019, The Lancet.

The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical utility of cerebrospinal fluid-derived circular RNAs in lung adenocarcinoma patients with brain metastases

Yi-long Wu, Xue Wu, Q. Ou, 2022, Journal of Translational Medicine.

Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early-Invasive Lung Adenocarcinoma.

Yi-long Wu, Jin-Ji Yang, Chao Zhang, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Diagnostics, therapeutics and RET inhibitor resistance for RET fusion-positive non-small cell lung cancers and future perspectives.

Qing Zhou, Chang Lu, 2021, Cancer treatment reviews.

Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.

N. Girard, M. Ahn, Melissa L. Johnson, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2021, Cancer cell.

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Jian Su, Qing Zhou, Hai-Yan Tu, 2016, Clinical Cancer Research.

Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC

Yi-long Wu, Yi-chen Zhang, Qing Zhou, 2016, Expert opinion on pharmacotherapy.

Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2016, Oncotarget.

The Resistance Mechanisms of Lung Cancer Immunotherapy

Shubin Wang, Qing Zhou, Fen Wang, 2020, Frontiers in Oncology.

Mutational landscape and characteristics of ERBB2 in non‐small cell lung cancer

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2020, Thoracic cancer.

Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer

Yi-long Wu, Xue Wu, Y. Shao, 2020, Journal for ImmunoTherapy of Cancer.

Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies

Yi-long Wu, Jin-Ji Yang, Chao Zhang, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer

Yi-long Wu, Chao Zhang, W. Zhong, 2017, Oncoimmunology.

Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Yi-long Wu, Jin-Ji Yang, S. Chuai, 2017, Clinical Cancer Research.

Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2021, Nature Communications.

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2010, Molecular Cancer.

Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC

Jin-Ji Yang, K. Yin, Xuchao Zhang, 2023, Cancers.

[Progress in Treatment of Advanced Squamous Cell Lung Cancer].

Qing Zhou, Ming Gao, 2020, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer

Qing Zhou, Yi-long Wu, W. Zhong, 2017, Oncotarget.

Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study

Jin-Ji Yang, Chongrui Xu, Xuchao Zhang, 2023, Cell reports. Medicine.

Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma component.

T. Mok, Yi-long Wu, Jin-Ji Yang, 2010, Clinical lung cancer.

Plasma extracellular vesicle microRNAs for pulmonary ground-glass nodules

Jing Qin, Yi-long Wu, Jin-Ji Yang, 2019, Journal of extracellular vesicles.

Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Toward an Expert Level of Lung Cancer Detection and Classification Using a Deep Convolutional Neural Network.

Yi-long Wu, Zai-yi Liu, Chao Zhang, 2019, The oncologist.

Impact of smoking status and pathologic type on epidermal growth factor receptor mutations in lung cancer.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2011, Chinese medical journal.

Prediction of unfavourable response to checkpoint blockade in lung cancer patients through an integrated tumour-immune expression score

Yi-long Wu, Jin-Ji Yang, K. Yin, 2021, Translational oncology.

ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer.

Yi-long Wu, J. Rigas, Yuh-Min Chen, 2019, Future oncology.

Intratumoral genetic and immune microenvironmental heterogeneity in T4N0M0 (diameter ≥ 7 cm) non‐small cell lung cancers

X. Yi, Xue-Ning Yang, W. Zhong, 2022, Thoracic cancer.

Genomic Signatures Define Three Subtypes of EGFR-Mutant Stage II-III NSCLC With Distinct Adjuvant Therapy Outcomes

W. Mao, Ying Cheng, Yi-long Wu, 2021 .

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?

Chongrui Xu, Yi-chen Zhang, Qing Zhou, 2017, Expert review of molecular diagnostics.

Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study.

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2015, Journal of Hematology & Oncology.

Applications of Circulating Tumor DNA in Immune Checkpoint Inhibition: Emerging Roles and Future Perspectives

Yi-chen Zhang, Zhi-hong Chen, Qing Zhou, 2022, Frontiers in Oncology.

Strategy on Patients with EGFR Mutation

T. Mok, M. Früh, L. Leung, 2015 .

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2017, Lung cancer.

Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China

T. Mok, Yi-long Wu, Wei Liu, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2020, Frontiers in Oncology.

Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC.

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2016, Clinical lung cancer.

Bevacizumab Plus Erlotinib in Chinese Patients with Untreated, EGFR-Mutated, Advanced NSCLC (ARTEMIS-CTONG1509): A Multicenter Phase 3 Study

Ying Cheng, Yi-long Wu, Zhi-yong Ma, 2020 .

MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2021, Experimental Hematology & Oncology.

Effects of epidermal growth factor receptor‐tyrosine kinase inhibitors alone on EGFR‐mutant non‐small cell lung cancer with brain metastasis

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2016, Thoracic cancer.

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2013, Lung cancer.

Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status

T. Mok, Yi-long Wu, Jin-Ji Yang, 2012, PloS one.

Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).

Ying Cheng, T. Mok, Yi-long Wu, 2021, Lung cancer.

Personalized medicine for non-small-cell lung cancer

T. Mok, H. Loong, L. Leung, 2010, Expert review of anticancer therapy.

The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2016, Oncotarget.

Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901).

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2020, Clinical lung cancer.

Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective study.

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2020, Lung cancer.

Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study

Yi-long Wu, L. Shen, D. Ye, 2020, Journal for immunotherapy of cancer.

A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002).

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2019, European journal of cancer.

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

Jian Su, Jun Zhao, Qing Zhou, 2018, BMC Cancer.

The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma

Jin-Ji Yang, Yilong Wu, Chongrui Xu, 2016, Oncotarget.

A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805).

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2014, Lung cancer.

Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal circulating tumor DNA Monitoring in Advanced EGFR-mutant Lung Adenocarcinoma under Gefitinib Treatment.

Ying Cheng, Yi-long Wu, Yuankai Shi, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial.

Ying Cheng, Yi-long Wu, Meizhuo Zhang, 2018, The Lancet. Respiratory medicine.

Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2016, Journal of Hematology & Oncology.

EGFR mutations in early‐stage and advanced‐stage lung adenocarcinoma: Analysis based on large‐scale data from China

Xing Gao, Chongrui Xu, Hong-Hong Yan, 2018, Thoracic cancer.

EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.

T. Mok, Yi-long Wu, Jin-Ji Yang, 2012, The oncologist.

Clinical management of third-generation EGFR inhibitor-resistant patients with advanced non-small cell lung cancer: Current status and future perspectives.

Yi-long Wu, Yi-chen Zhang, Qing Zhou, 2019, Cancer letters.

Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level

Jin-Ji Yang, Yilong Wu, Chongrui Xu, 2019, BMC Cancer.

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

Yi-long Wu, Jin-Ji Yang, Hong-Hong Yan, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Emerging paradigms in targeted treatments for Asian patients with NSCLC

Yi-long Wu, Qing Zhou, E. Ke, 2015, Expert opinion on pharmacotherapy.

Lung Cancers with Concomitant EGFR Mutations and ALK Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation

T. Mok, Yi-long Wu, Jin-Ji Yang, 2014, Clinical Cancer Research.

Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors ? -- A literature-based meta-analysis

Yi-long Wu, Chongrui Xu, Qing Zhou, 2012, Journal of Hematology & Oncology.

Single Nucleotide Polymorphisms in VTI1A Gene Contribute to the Susceptibility of Chinese Population to Non-Small Cell Lung cancer

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2015, The International journal of biological markers.

Rare discrepancies in a driver gene alteration within histologically heterogeneous primary lung cancers.

Jin-Ji Yang, Xue-Ning Yang, W. Zhong, 2015, Lung cancer.

Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma

W. Zhong, S. Dong, Weidong Chen, 2022, Journal for ImmunoTherapy of Cancer.

Real-World Scenario of Patients With Lung Cancer Amid the Coronavirus Disease 2019 Pandemic in the People’s Republic of China

Yi-long Wu, Jin-Ji Yang, Chao Zhang, 2020, JTO clinical and research reports.

Clinical features and intervention timing in patients with pregnancy-associated non-small-cell lung cancer

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2021, Journal of thoracic disease.

Clinical trials for lung cancer in China.

Yi-long Wu, W. Zhong, F. Niu, 2014, Translational lung cancer research.

Uncommon ALK fusion partners in advanced ALK-positive non-small-cell lung cancer.

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2018 .

Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer

X. Yi, Jin-Ji Yang, Xue-Ning Yang, 2022, Cancer discovery.

A family history of cancer and lung cancer risk in never-smokers: A clinic-based case-control study.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2015, Lung cancer.

A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel

Ying Cheng, Yi-long Wu, B. Han, 2017, ESMO Open.

The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer

Yi-long Wu, Yi-chen Zhang, Qing Zhou, 2017, Journal of Hematology & Oncology.

BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2013, Molecular Cancer.

Integration of comprehensive genomic profiling, tumor mutational burden, and PD‐L1 expression to identify novel biomarkers of immunotherapy in non‐small cell lung cancer

Juan Zhao, Li Liu, Xiaowei Dong, 2021, Cancer medicine.

Safety and efficacy of abivertinib (AC0010), a third-generation EGFR tyrosine kinase inhibitor, in Chinese patients with EGFR-T790M positive non-small cell lung cancer (NCSLC).

Ying Cheng, Yi-long Wu, B. Han, 2019, Journal of Clinical Oncology.

P1.01-018 Acquired Resistance to Crizotinib in Advanced NSCLC with De Novo MET Overexpression

Jin-Ji Yang, W. Zhong, Z. Xie, 2017 .

A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)

P. Yu, Xin Zhang, Yi Hu, 2017, BMC Cancer.

Care of adolescents and young adults with cancer in Asia: results of an ESMO/SIOPE/SIOP Asia survey

K. Yonemori, S. Bielack, J. Douillard, 2019, ESMO Open.

Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2018, Lung cancer.

Lorlatinib for Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer: Primary Efficacy and Safety From a Phase 2 Study in China.

Ying Cheng, C. Bai, He-long Zhang, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

840P Famitinib malate plus camrelizumab for recurrent platinum-resistant ovarian/fallopian tube/primary peritoneal cancer and advanced cervical cancer: An open-label, multicenter phase II study

G. Lou, Xuehao Wang, X. Wu, 2020 .

EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third‐Generation EGFR Tyrosine Kinase Inhibitor Osimertinib

Yi-long Wu, Jin-Ji Yang, Z. Wang, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2019, EBioMedicine.

A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)

Yi-long Wu, P. Yu, Yiping Zhang, 2017, BMC Cancer.

The changing landscape of clinical trial and approval processes in China

Yi-long Wu, Qing Zhou, Zhimin Yang, 2017, Nature Reviews Clinical Oncology.

Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial

Ying Cheng, Jin-Ji Yang, Xue-Ning Yang, 2023, Signal Transduction and Targeted Therapy.

Expert consensus on treatment for stage III non‐small cell lung cancer

W. Liang, Jin-Ji Yang, Long Chen, 2023, Medicine Advances.

Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor Cells

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2017, Clinical Cancer Research.

NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer.

N. Shire, Jian-hua Chang, Si Sun, 2023, Lung cancer.

Developing CSCO Lung Cancer Practice Guidelines Stratified by Resource Availability and Treatment Value

Yi-long Wu, Qing Zhou, 2016, Journal of global oncology.

Correlation of exosomal microRNA clusters with bone metastasis in non-small cell lung cancer

Yi-long Wu, Xue Wu, Y. Shao, 2020, Clinical & Experimental Metastasis.

Prognostic value of serum cytokeratin 19 fragments (Cyfra 21-1) in patients with non-small cell lung cancer

Lin Xu, M. Qiu, Youtao Xu, 2015, Scientific Reports.

MA16.06 Phase I/II Study of AC0010, Mutant-Selective EGFR Inhibitor, in Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR T790M Mutation

Ying Cheng, Yi-long Wu, Li Zhang, 2017 .

Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506).

Yi-long Wu, P. Yu, Yiping Zhang, 2018, Lung cancer.

Heterogeneity in the immune microenvironment of bone metastasis in driver‐positive non‐small cell lung cancer

Weihua Luo, Xuchao Zhang, Dongqin Zhu, 2023, Molecular carcinogenesis.

High SHP2 expression determines the efficacy of PD‐1/PD‐L1 inhibitors in advanced KRAS mutant non‐small cell lung cancer

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2021, Thoracic Cancer.

SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer

D. Day, Lifeng Wang, H. Pan, 2023, Journal for ImmunoTherapy of Cancer.

Sintilimab versus pembrolizumab in monotherapy or combination with chemotherapy as first-line therapy for advanced non–small cell lung cancer: Results from phase 2, randomized clinical trial (CTONG1901).

Jin-Ji Yang, Xuchao Zhang, Hong-Hong Yan, 2022, Journal of Clinical Oncology.

Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC

C. Chiu, Dong-Wan Kim, G. Chang, 2023, JTO clinical and research reports.

Emerging challenges of advanced squamous cell lung cancer

Yi-long Wu, Yi-chen Zhang, Qing Zhou, 2016, ESMO Open.

EGFR/KRAS Mutations and Gefitinib Therapy in Chinese NSCLC Patients

Chongrui Xu, Qing Zhou, Zhen Wang, 2008, Oncology Research and Treatment.

Coexistence of MET exon 14 mutations with EGFR mutations in non-small cell lung cancer.

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2017 .

Different dissecting orders of the pulmonary bronchus and vessels during right upper lobectomy are associated with surgical feasibility and postoperative recovery for lung cancer patients

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2017, Chinese journal of cancer.

Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2018, Thoracic cancer.

Circulating tumor cells dynamics during chemotherapy predict survival and response in advanced non-small-cell lung cancer patients

Jin-Ji Yang, W. Feng, Xuchao Zhang, 2023, Therapeutic advances in medical oncology.

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2018, BMC Cancer.

Accidental invisible intrathoracic disseminated pT4-M1a: a distinct lung cancer with favorable prognosis.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2015, Journal of thoracic disease.

Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.

Yi-long Wu, Jin-Ji Yang, Jie Huang, 2021, Clinical lung cancer.

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2016, Oncotarget.

Epidermal growth factor receptor is associated with the onset of skeletal related events in non-small cell lung cancer

Yi-long Wu, Jin-Ji Yang, Shu-Mei Huang, 2017, Oncotarget.

NGS to reveal heterogeneity between cerebrospinal fluid and plasma ctDNA among non-small cell lung cancer patients with leptomeningeal carcinomatosis.

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2017 .

局部热消融在NSCLC中的临床应用现状与挑战

Q. Gou, Xiaoming Chen, Zejian Zhou, 2020, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Distribution and prognosis of uncommon metastases from non-small cell lung cancer

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2016, BMC Cancer.

P1.01-112 Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC

Ying Cheng, S. Ramalingam, M. Saggese, 2018, Journal of Thoracic Oncology.

Stereotactic ablative radiotherapy versus lobectomy for stage I non‐small cell lung cancer: A systematic review

Siwei Wang, Lin Xu, M. Qiu, 2018, Thoracic cancer.

GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy

Yi-long Wu, Jian-hua Chang, Gang Wu, 2020, Translational lung cancer research.

Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2017, Oncotarget.

A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2014, BMC Cancer.

A Clinical Model to Estimate the Pretest Probability of Lung Cancer, Based on 1198 Pedigrees in China

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial

Yangqiu Li, Jin-Ji Yang, Chongrui Xu, 2023, Nature Network Boston.

A comprehensive model of genetic-features predicts outcome of personalized adjuvant treatment in resected EGFR-mutant stage II-IIIA NSCLC: Results from a phase III trial (CTONG 1104-ADJUVANT)

W. Mao, Q. Wang, W. Zhong, 2019, Annals of Oncology.

A phase II trial comparing pemetrexed with gefitinib as the second-line treatment of nonsquamous NSCLC patients with wild-type EGFR (CTONG0806).

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2013 .

Lung cancer management in the Asia-Pacific region: what's the difference compared with the United States and Europe? Results of the Second Asia Pacific Lung Cancer Conference.

Yi-long Wu, Qing Zhou, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level

Jin-Ji Yang, Yilong Wu, Chongrui Xu, 2019, BMC Cancer.

The spatiotemporal evolution of EGFR C797S mutation in EGFR-mutant non-small cell lung cancer: opportunities for third-generation EGFR inhibitors re-challenge.

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2019, Science bulletin.